Rheumatology International

, Volume 32, Issue 8, pp 2307–2311

Serum levels of macrophage migration inhibitory factor are associated with rheumatoid arthritis course

  • Mara Anaís Llamas-Covarrubias
  • Yeminia Valle
  • Rosa Elena Navarro-Hernández
  • Iris Paola Guzmán-Guzmán
  • María Guadalupe Ramírez-Dueñas
  • Héctor Rangel-Villalobos
  • Ciro Estrada-Chávez
  • José Francisco Muñoz-Valle
Original Article

Abstract

Rheumatoid arthritis (RA) is an inflammatory autoimmune disease of unknown etiology. Many cytokines have been found to be associated with RA pathogenesis and among them is macrophage migration inhibitory factor (MIF). The aim of this study was to determine whether MIF serum levels are associated with RA course, clinical activity, and clinical biomarkers of the disease. MIF levels were determined in serum samples of 54 RA patients and 78 healthy subjects (HS) by enzyme-linked immunosorbent assay (ELISA). Disease activity was evaluated using the DAS28 score. Patients were subgrouped according to disease activity and years of evolution of disease. Statistical analysis was carried out by SPSS 10.0 and GraphPad Prism 5 software. RA patients presented increased levels of MIF as compared to HS. MIF levels were raised on early stages of RA and tend to decrease according to years of evolution. Moreover, MIF levels positively correlated with rheumatoid factor in RA patients and with C reactive protein in all individuals studied. Our findings suggest that MIF plays a role in early stages of RA.

Keywords

Rheumatoid arthritis MIF Clinical activity Disease evolution 

Abbreviations

RA

Rheumatoid arthritis

MIF

Macrophage migration inhibitory factor

HS

Healthy subjects

RF

Rheumatoid factor

CRP

C reactive protein

MMPs

Matrix metalloproteinases

FLS

Fibroblast like synoviocytes

DMARDs

Disease-modifying antirheumatic drugs

NSAIDs

Non-steroidal anti-inflammatory drugs

PLA2

Phospholipase A2

COX-2

Cyclooxigenase 2

References

  1. 1.
    McInnes IB, Schett G (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7:429–442PubMedCrossRefGoogle Scholar
  2. 2.
    David JR (1966) Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA 56:72–77PubMedCrossRefGoogle Scholar
  3. 3.
    Calandra T, Roger T (2003) Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol 3:791–800PubMedCrossRefGoogle Scholar
  4. 4.
    Denkinger CM, Metz C, Fingerle-Rowson G et al (2004) Macrophage migration inhibitory factor and its role in autoimmune diseases. Arch Immunol Ther Exp 52:389–400Google Scholar
  5. 5.
    Willeke P, Gaubitz M, Schotte H et al (2007) Increased serum levels of macrophage migration inhibitory factor in patients with primary Sjögren′s syndrome. Arthritis Res Ther 9:R43PubMedCrossRefGoogle Scholar
  6. 6.
    Santos LL, Morand EF (2009) Macrophage migration inhibitory factor: a key cytokine in RA, SLE and atherosclerosis. Clin Chim Acta 399:1–7. doi:10.1016/j.cca.2008.09.014 PubMedCrossRefGoogle Scholar
  7. 7.
    Leech M, Metz C, Hall P et al (1999) Macrophage migration inhibitory factor in rheumatoid arthritis: evidence of proinflamatory function and regulation by glucocorticoids. Arthritis Rheum 42:1601–1608PubMedCrossRefGoogle Scholar
  8. 8.
    Prevoo MLL, Van’T Hof MA, Kuper HH et al (1995) Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38:44–48PubMedCrossRefGoogle Scholar
  9. 9.
    Weinblatt ME, Kremer JM, Bankhurst AD et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340:253–259PubMedCrossRefGoogle Scholar
  10. 10.
    Thaler K, Chandiramani DV, Hansen RA et al (2009) Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug Effectiveness Review Project. Biologics 3:485–498PubMedGoogle Scholar
  11. 11.
    Nishimoto N, Miyasaka N, Yamamoto K et al (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580–1584PubMedCrossRefGoogle Scholar
  12. 12.
    Leech M, Metz C, Santos L, Peng et al (1998) Involvement of macrophage migration inhibitory factor in the evolution of rat adjuvant arthritis. Arthritis Rheum 41:910–917PubMedCrossRefGoogle Scholar
  13. 13.
    Onodera S, Ohshima S, Tohyama H et al (2007) A novel DNA vaccine targeting macrophage migration inhibitory factor protects joints from inflammation and destruction in murine models of arthritis. Arthritis Rheum 56:521–530PubMedCrossRefGoogle Scholar
  14. 14.
    Leech M, Metz C, Bucala R et al (2000) Regulation of macrophage migration inhibitory factor by endogenous glucocorticoids in rat adjuvant-induced arthritis. Arthritis Rheum 43:827–833PubMedCrossRefGoogle Scholar
  15. 15.
    Martinez A, Orozco G, Varadé J et al (2007) Macrophage migration inhibitory factor gene: influence on rheumatoid arthritis susceptibility. Hum Immunol 68:744–747PubMedCrossRefGoogle Scholar
  16. 16.
    Radstake TR, Sweep FC, Welsing P et al (2005) Correlation of rheumatoid arthritis severity with the genetic functional variants and circulating levels of macrophage migration inhibitory factor. Arthritis Rheum 52:3020–3029PubMedCrossRefGoogle Scholar
  17. 17.
    Wheelhouse NM, Dowidar N, Dejong CHC et al (2006) The effects of macrophage migratory inhibitory factor on acute-phase protein production in primary human hepatocytes. Int J Mol Med 18:957–961PubMedGoogle Scholar
  18. 18.
    Morand EF, Leech M, Weedon H et al (2002) Macrophage migration inhibitory factor in rheumatoid arthritis: clinical correlations. Rheumatology (Oxford) 41:558–562CrossRefGoogle Scholar
  19. 19.
    Bacher M, Metz CN, Calandra T, Mayer et al (1996) An essential regulatory role for macrophage migration inhibitory factor in T-cell activation. Proc Natl Acad Sci USA 93:7849–7854PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Mara Anaís Llamas-Covarrubias
    • 1
  • Yeminia Valle
    • 2
  • Rosa Elena Navarro-Hernández
    • 2
  • Iris Paola Guzmán-Guzmán
    • 1
  • María Guadalupe Ramírez-Dueñas
    • 3
  • Héctor Rangel-Villalobos
    • 4
  • Ciro Estrada-Chávez
    • 5
  • José Francisco Muñoz-Valle
    • 2
    • 6
  1. 1.Doctorado en Ciencias Biomédicas, Centro Universitario de Ciencias de la SaludUniversidad de GuadalajaraGuadalajaraMexico
  2. 2.IIRSME, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la SaludUniversidad de GuadalajaraGuadalajaraMexico
  3. 3.Laboratorio de Inmunología, Departamento de Fisiología, Centro Universitario de Ciencias de la SaludUniversidad de GuadalajaraGuadalajaraMexico
  4. 4.Instituto de Investigación en Genética Molecular, Centro Universitario de la CiénegaUniversidad de GuadalajaraOcotlánMexico
  5. 5.Centro de Investigación y Asistencia en Tecnológica y Diseño del Estado de JaliscoGuadalajaraMexico
  6. 6. IIRSME, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de GuadalajaraZapopanMexico

Personalised recommendations